. Overview We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category. We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the patient-care value chain, which is counter-positioned with the send-out-testing central laboratory model. Our decentralized approach also puts testing in the ...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001642380-26-000004 | EDGAR | 80K words |
| 2025-03-24 | 2024-12-31 | 0000950170-25-043852 | EDGAR | — |
| 2024-04-16 | 2023-12-31 | 0001493152-24-014720 | EDGAR | — |
| 2023-04-12 | 2022-12-31 | 0001493152-23-012005 | EDGAR | — |
| 2022-03-11 | 2021-12-31 | 0001493152-22-006677 | EDGAR | — |
| 2021-03-19 | 2020-12-31 | 0001493152-21-006465 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001493152-20-004738 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001493152-19-004549 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001140361-18-016477 | EDGAR | — |
| 2017-02-27 | 2016-12-31 | 0001140361-17-009369 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274266 | EDGAR | 46K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106552 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069213 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125365 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001493152-24-030793 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019842 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001493152-23-040121 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001493152-23-027603 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-016796 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031415 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001493152-22-022151 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001493152-22-013051 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001493152-26-012915 | EDGAR | 8K words |
| 2026-02-26 | 0001493152-26-008169 | EDGAR | — |
| 2026-02-12 | 0001493152-26-006473 | EDGAR | — |
| 2026-02-11 | 0001493152-26-006117 | EDGAR | — |
| 2025-11-10 | 0001493152-25-021513 | EDGAR | — |
| 2025-10-02 | 0001493152-25-016685 | EDGAR | — |
| 2025-09-19 | 0001493152-25-014240 | EDGAR | — |
| 2025-08-11 | 0001641172-25-022974 | EDGAR | — |
| 2025-07-02 | 0001641172-25-017590 | EDGAR | — |
| 2025-06-17 | 0001641172-25-015338 | EDGAR | — |
271 total filings indexed. 239 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001642380 |
| Ticker | IMDX |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | CA |
| Website | https://www.imdxinc.com |
| Listed | 2015-12-30 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report